In science there are often too many choices to make. Nammi Therapeutics Inc.’s CEO, David Stover, told BioWorld that he makes narrowing therapeutic options a core company principle. The redundancy of immune regulatory pathways in cancer treatments is a case in point.

Xenter Inc. has officially launched, positioning itself as the first startup device/data/drug med-tech company. The company is developing wireless solutions for interventional cardiology, interventional radiology and neurointerventional radiology.

Xenter Inc. has officially launched, positioning itself as the first startup device/data/drug med-tech company. The company is developing wireless solutions for interventional cardiology, interventional radiology and neurointerventional radiology. The company’s goal is to take the medical devices that have been used most ubiquitously throughout medicine, one by one, and replace them with smart technologies that incorporate such things as software, sensors and signals technologies.

Shoreline Biosciences Inc., a San Diego-based company developing allogenic natural killer and macrophage cellular therapies for cancer and other diseases, has raised $43 million in a financing led by Boxer Capital.

Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.

PERTH, Australia – Ferronova Ltd. has developed an injectable magnetic and fluorescent tracer that can map the spread of cancer in the lymph nodes more accurately for improving the staging of complex cancers. The polymer-coated iron oxide nanoparticles show more detailed assessment of sentinel lymph nodes and detect micro-metastasis and isolated tumor cells that would otherwise not be detected.

It’s a first for Larry Miller. In his 30 years of working in pharma, he has never run a company that didn’t have a pack of near competitors scrambling to develop a therapy. “Not even close,” he told BioWorld. Miller, the CEO of Apnimed Inc., just saw the company close on a $25 million series B to help drive its lead program, a once-daily, oral obstructive sleep apnea (OSA) therapy, into a phase III registrational trial.

The animal world is full of species that can perform astonishing, and sometimes disgusting, feats. Take vultures, for example. “They eat this rotten meat that is full of pathogens and toxins, and they stay healthy,” Neta Raab told BioWorld. Raab is the co-founder and CEO of Wild Biotech Ltd., an Israeli startup that is seeking to understand gut microbiome contributions to these animal superpowers, and harness them for therapeutic use.

Zenas Biopharma LLC launched on March 23 as a U.S. funded cross-border biotech company targeting autoimmune diseases in China. The company, headquartered in Miromar Lakes, Fla., is founded and funded by Tellus Bioventures LLC and Fairmount Funds Management LLC.

Eliem Therapeutics Inc. is old-fashioned in the useful ways. The company is going after extremely large indications, including chronic pain and major depression. “We’re really passionate about these large markets,” Eliem President and CEO Bob Azelby told BioWorld. “These patients live in the shadows… There’s so many people suffering.”